• Transforming the way heart disease is diagnosed and treated, HeartFlow’s artificial intelligence-enabled software platform brings precision heart care to cardiology.
• The HeartFlow Analysis is the first and only non-invasive tool to assist with the diagnosis, management and treatment of patients with heart disease, the most common type of cardiovascular disease which accounts for one in three deaths and $1 out of every $6 of U.S. healthcare spend¹.
• HeartFlow has demonstrated higher diagnostic accuracy compared to other non-invasive tests² with an 83% reduction in unnecessary invasive angiograms, resulting in a significant reduction in the total cost of care³.
• Merging with Longview Acquisition Corp. II (an affiliate of Glenview Capital Management) enables HeartFlow to accelerate adoption and supports the Company’s mission to transform the heart disease care continuum.
• The transaction is also supported by existing institutional shareholders including Baillie Gifford, Blue Venture Fund, HealthCor Partners, and Wellington Management.
• The combined pro forma enterprise value is approximately $2.4 billion, with an estimated $400 million in cash after closing.
• A webcast to discuss the highlights of the proposed transaction is available at www.heartflow.com/investors.

REDWOOD CITY, Calif. and NEW YORK, NY – July 15, 2021 — HeartFlow Holding, Inc. (“HeartFlow”, or the “Company”), the leader in revolutionizing precision heart care, and Longview Acquisition Corp. II (NYSE: LGV)(“Longview”), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC (“Glenview”), announced today that they have entered into a definitive business combination agreement that will support HeartFlow’s vision of revolutionizing precision heart care.